126 results
Page 3 of 7
6-K
EX-99.1
vq4i91gb4khqxwwr8
16 Apr 21
Current report (foreign)
4:10pm
424B5
4jdi v4z6s
10 Feb 21
Prospectus supplement for primary offering
4:53pm
424B5
ul8x8r2uztdezm
9 Feb 21
Prospectus supplement for primary offering
5:24pm
6-K
EX-99.1
3whn8kfe2o8
14 Jan 21
Current report (foreign)
7:06am
6-K
EX-99.1
zcryxt
17 Dec 20
Mereo BioPharma and Ultragenyx Announce Collaboration and License
5:16pm
6-K
EX-99.1
p2cdbn 4kn6c6m0b
16 Nov 20
Current report (foreign)
7:27am
6-K
EX-99.1
ig6 zcjlbq8ufw
12 Nov 20
Current report (foreign)
6:15am
424B5
tu0e8
23 Oct 20
Prospectus supplement for primary offering
4:40pm
6-K
EX-99.1
uwdct9qdt ssw
20 Oct 20
Mereo BioPharma Appoints Christine Fox as Chief Financial Officer and Heidi Petersen as Senior Vice President, Regulatory Affairs
7:12am
6-K
EX-99.1
eu803v
19 Oct 20
Current report (foreign)
8:10am
F-3
52u6x5 u7m0m74nk6n
6 Oct 20
Shelf registration (foreign)
4:25pm
6-K
EX-99.2
rnxnz3vkvi
29 Sep 20
Current report (foreign)
7:08am
6-K
EX-99.1
ntdcm
29 Sep 20
Current report (foreign)
7:08am
6-K
EX-99.1
z5ablwlcb4ox9n97lrm
28 Sep 20
Mereo BioPharma Announces Changes to Board of Directors
8:08am
6-K
EX-99.1
hhazh m4v0b8uf
24 Sep 20
Mereo BioPharma Receives FDA Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis Imperfecta
8:48am
F-3
pzqth7w9iiasknpmeaoa
6 Jul 20
Shelf registration (foreign)
4:58pm
POS AM
k7byeph9
2 Jul 20
Prospectus update (post-effective amendment)
3:57pm